Q-Plex Custom Assays

Targeted panels for specific research needs delivered through innovative multiplexing technologies. These assays offer custom target combinations, specialized applications, and advanced multiplexing capabilities tailored to individual laboratory requirements.

Custom quantitative polymerase chain reaction assays and complete kits manufactured for molecular diagnostics applications. Includes reagent formulation, kit assembly, quality control testing, and validation according to ISO 13485 and FDA 21 CFR Part 820 standards.

Multiple ELISA-based immunoassays for quantitative protein and biomarker detection in diagnostic applications. Suitable for laboratory and clinical settings.

A line of enzyme-linked immunosorbent assay (ELISA) products for quantitative and qualitative immunological testing. These assays are used across clinical and research laboratories for various diagnostic applications.

Allplex Respiratory Panel Assays are high-multiplex real-time PCR assays designed to simultaneously detect multiple respiratory pathogens in a single test. These syndromic panels integrate seamlessly into automated molecular diagnostic workflows, enabling rapid and comprehensive pathogen identification for respiratory infections. The assays leverage advanced multiplex chemistry technology for efficient infectious disease diagnosis and surveillance.

Allplex STI Assays are multiplex real-time PCR tests for simultaneous detection of sexually transmitted infection pathogens. These syndromic panel assays integrate seamlessly into molecular diagnostic workflows for rapid, automated pathogen identification and surveillance.

Custom quantitative PCR assays for molecular diagnostics across oncology and infectious disease applications. Developed and manufactured under ISO 13485 compliance with full regulatory support for clinical and research use.

Multiplexing BioChip for rapid, simultaneous detection of multiple analytes in clinical specimens. FDA 510(k) cleared platform enables high-throughput diagnostic testing including fentanyl, oral fluid biomarkers, and other substances of abuse. CLIA-waived assays deliver results in minutes for point-of-care and laboratory use.

Market-leading diagnostic tests that empower laboratories to deliver comprehensive, actionable answers clinicians need to treat patients correctly. These tests detect pathogens causing infections and provide clinically relevant information to support patient management and inform treatment decisions through cost-effective, multiplexed assays.

Multiplex real-time PCR premix with probe-based detection for simultaneous quantification of multiple DNA targets. Designed for complex molecular diagnostic assays.

Contract development service for custom ELISA assays with expert biomarker validation and format optimization. Includes assay design, optimization, and manufacturing support from concept through commercialization.

Advanced immunofluorescence assays designed for precise tracking of biomarkers related to diabetes, hormones, inflammation/coagulation, cardiovascular and bone health. These assays are compatible with the Qassay Digital Rapid Test Reader platform.